In the annual general meeting of 8 May 2007, Arpidas shareholders approved the appointment of Michel Pettigrew MBA as a non-executive member of the Board of Directors of Arpida Ltd. Michel Pettigrew is currently Chief Operating Officer at Ferring Pharmaceuticals, a privately owned research-driven specialty biopharmaceutical company. In this position, he oversees all sales, marketing and manufacturing activities around the world. In earlier positions, he has worked for Procter & Gamble and Bristol-Myers Squibb in North-America, Europe and Asia.
In view of the new growth phase that Arpida is entering, the Board of Directors has decided to establish two new committees. The task of the newly established Research & Development Committee is to provide strategic guidance to Arpidas activities in this field. The committee consists of Prof Dr Axel Kleemann (chair) and Prof Dr Nam-Hai Chua. The task of the Commercialisation Committee is to define the strategic focus and framework for the (pre-) marketing efforts. The committee is chaired by Dr Jurgen Raths and has Michel Pettigrew, MBA and Dr Andre Lamotte as members.
The Compensation and Nomination committees have been merged into one which consists of Prof Dr Nam-Hai Chua (chair), Dr Andre Lamotte and Dr Hans Funfschilling. The Finance & Audit Committee consists of Dr Hans Funfschilling (chair), Prof Dr Axel Kleemann and Michel Pettigrew, MBA.
Based on current expectations, intravenous iclaprim could be launched
in its first indication (cSSSI) in the USA in the course of 2008. Arpida is
convinced it can market the drug in the USA without the need for a partner.
The potential profitability of this approach clearly exceeds that of an
outlicensing scenario. In Europe, the approach is flexible: Arpida could
handle the marketing itself, but does not exclude working with partners.
For all other regions, Arpida will be loo
Copyright©2007 PR Newswire.
All rights reserved